Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24. BMY’s shares lost nearly 11.6% in the preceding six sessions. On a year-to-date basis,

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.